Recently published data from the German Gastric Cancer Study Group showed that the addition of the HER2 antibody trastuzumab to FLOT (loading dose 6 mg/kg, then 4 mg/kg every 2 weeks in combination with FLOT, then 9 cycles of trastuzumab monotherapy) resulted in promising histopathological response rates in 56 patients (pCR 21%, almost pCR 25%) and EFS (median 42.5 months, 3-year survival 82%) without unexpected toxicity [34]. Here, ERBB2 is linked to gastric cancer.